drugset / Trial / NCT05045716
A Study of Subcutaneous Lecanemab in Healthy Participants
RandomizedParallel-groupOpen-labelBasic science
Summary
The primary purpose of this study is to determine the absolute bioavailability and pharmacokinetic (PK) profile of a single dose of lecanemab when administered subcutaneously (SC) in healthy participants.
Timeline
- Start
- 2021-09-07
- Primary completion
- 2021-12-07
- Completion
- 2021-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lecanemab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Lecanemab | Monoclonal antibody | 700 mg | Intravenous |
Indications
No indication recorded.